Sinovac to Host Conference Call to Report Third Quarter 2008 Financial Results

Wednesday, November 12, 2008 General News J E 4
BEIJING, Nov. 12 Sinovac Biotech Ltd. (Amex: SVA),a leading provider of vaccines in China, today announced that it will host aconference call on Tuesday, November 18, 2008 at 8:00 p.m. ET to review theCompany's third quarter financial results for the period ended September 30,2008 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00p.m. ET on November 18 until December 2, 2008. To access the replay, pleasedial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference theaccount number 3055 and the access code 303493.

A live audio webcast of the call will also be available from the Investorssection on the corporate web site at . A webcast replaycan be accessed on the corporate website beginning November 18, 2008 and thereplay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available on itswebsite, . To be added to our distribution list, pleaseemail: .For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Phone: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email:

SOURCE Sinovac Biotech Ltd.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Amedica Receives CE Mark for the World's First FDA...
WellPoint Introduces International Medical Tourism...